Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5867 Articles

Jon C. Ogg | Mar 11, 2013 at 9:20 AM EDT

Omthera Pharmaceuticals Files for IPO

ThinkstockOmthera Pharmaceuticals has joined the wave of companies wanting to come public. Omthera is a clinical stage biotech and will…

Jon C. Ogg | Mar 8, 2013 at 9:00 AM EST

Pharmacyclics Does Smart and Opportunistic Capital Raise After Huge Run Up

ThinkstockPharmacyclics Inc. (NASDAQ: PCYC) has had a monster stock performance, with gains of much more than 200% over the past…

Jon C. Ogg | Mar 5, 2013 at 11:40 AM EST

Nymox Tries for Recovery on Safety Profile of NX-1207 for Prostate Cancer

ThinkstockNymox Pharmaceutical Corp. (NASDAQ: NYMX) took a mystery beating last Friday, to the point that a single stock circuit breaker was triggered…

Paul Ausick | Mar 5, 2013 at 7:55 AM EST

J&J, Bayer Fail to Gain FDA Approval for Blood Thinner

ThinkstockThe U.S. Food and Drug Administration (FDA) last night rejected an application from Johnson & Johnson (NYSE: JNJ) and Germany’s…

Jon C. Ogg | Mar 1, 2013 at 3:06 PM EST

Pharma Merger/Buyout Hunt Continues in Biotech, Valuations Under Focus

ThinkstockThe hunt by Big Pharma stocks for smaller drug companies and biotech stocks continues. A report citing “sources” from Dow…

Jon C. Ogg | Mar 1, 2013 at 11:10 AM EST

Daily ETF Folly: Why There Is No True Biotech Representation in ETFs

Thinkstock24/7 Wall St. is taking a daily aim at the world exchange-traded funds (ETFs). Many are great, and many are…

Jon C. Ogg | Feb 28, 2013 at 12:50 PM EST

ETF Folly: Biotech ETFs, Nothing but Confusion

Thinkstock24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or…

Jon C. Ogg | Feb 25, 2013 at 5:08 PM EST

VIVUS Obesity Drug Sales Only About 60% of Expectations

ThinkstockVIVUS Inc. (NASDAQ: VVUS) reported a quarterly loss of $0.56 per share on Monday, but this was not an earnings…

Jon C. Ogg | Feb 25, 2013 at 11:25 AM EST

FDA Response Letter Takes over $100M from Dynavax Value

ThinkstockDynavax Technologies Corp. (NASDAQ: DVAX) was a small cap stock even before today’s news, but a complete response letter from…

Jon C. Ogg | Feb 25, 2013 at 8:15 AM EST

Deadly Dialysis Injection Recall Implodes Affymax

ThinkstockAnother big implosion is taking place in the world of biotech and biohealth. Affymax Inc. (NASDAQ: AFFY) and Takeda Pharmaceutical…

Jon C. Ogg | Feb 22, 2013 at 9:55 AM EST

Celsion Raises Much Needed Capital

ThinkstockCelsion Corp. (NASDAQ: CLSN) was one of the more recent biotech implosions we have monitored. The company’s situation looked dire, and…

Jon C. Ogg | Feb 22, 2013 at 9:15 AM EST

Biotech and Bioheath Stocks Raising Capital, Secondary Offerings

ThinkstockIt is not unusual to see biotech and biohealth companies raise cash after good news. After all, these companies either need…

Jon C. Ogg | Feb 21, 2013 at 5:20 PM EST

Europe Denies Obesity Drug Approval

ThinkstockIf you are obese in Europe, you are not about to get a little pill to take to help you change.…

Jon C. Ogg | Feb 21, 2013 at 8:15 AM EST

Repros Blasts Off After FDA Study Clearance

ThinkstockRepros Therapeutics Inc. (NASDAQ: RPRX) is surging on clinical update news this Thursday. The company’s Androxal Phase 3 program has…

Jon C. Ogg | Feb 20, 2013 at 4:27 PM EST

Ambit Biosciences Files for IPO

ThinkstockAmbit Biosciences Corp. has filed its paperwork with the Securities and Exchange Commission to come public via an initial public…

1 … 306 307 308 309 310 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Omthera Pharmaceuticals Files for IPO

Pharmacyclics Does Smart and Opportunistic Capital Raise After Huge Run Up

Nymox Tries for Recovery on Safety Profile of NX-1207 for Prostate Cancer

J&J, Bayer Fail to Gain FDA Approval for Blood Thinner

Pharma Merger/Buyout Hunt Continues in Biotech, Valuations Under Focus

Daily ETF Folly: Why There Is No True Biotech Representation in ETFs

ETF Folly: Biotech ETFs, Nothing but Confusion

VIVUS Obesity Drug Sales Only About 60% of Expectations

FDA Response Letter Takes over $100M from Dynavax Value

Deadly Dialysis Injection Recall Implodes Affymax

Celsion Raises Much Needed Capital

Biotech and Bioheath Stocks Raising Capital, Secondary Offerings

Europe Denies Obesity Drug Approval

Repros Blasts Off After FDA Study Clearance

Ambit Biosciences Files for IPO

Wall Street Is Betting P&G’s Dividend Growth Ends. The Cash Flow Suggests That’s Not Happening

Strategy (MSTR) vs BlackRock’s IBIT: Which Bitcoin Bet Has Held Up Better in 2026?

Social Security’s 2027 Raise Looks Like 3.8%. Here’s How Income Investors Give Themselves a Bigger One

Her Physical Therapist Said Medicare’s $2,480 Limit Had Been Reached. That Number Is Not a Coverage Cap.

He "Retired" From Farming and Leased Out the Acres. Telling the Tenant What to Plant Kept Him Self-Employed.

Wall Street Is Betting P&G’s Dividend Growth Ends. The Cash Flow Suggests That’s Not Happening

Strategy (MSTR) vs BlackRock’s IBIT: Which Bitcoin Bet Has Held Up Better in 2026?

Health and Healthcare Articles

All Health and Healthcare Articles

Omthera Pharmaceuticals Files for IPO

Pharmacyclics Does Smart and Opportunistic Capital Raise After Huge Run Up

Nymox Tries for Recovery on Safety Profile of NX-1207 for Prostate Cancer

J&J, Bayer Fail to Gain FDA Approval for Blood Thinner

Pharma Merger/Buyout Hunt Continues in Biotech, Valuations Under Focus

Daily ETF Folly: Why There Is No True Biotech Representation in ETFs

ETF Folly: Biotech ETFs, Nothing but Confusion

VIVUS Obesity Drug Sales Only About 60% of Expectations

FDA Response Letter Takes over $100M from Dynavax Value

Deadly Dialysis Injection Recall Implodes Affymax

Celsion Raises Much Needed Capital

Biotech and Bioheath Stocks Raising Capital, Secondary Offerings

Europe Denies Obesity Drug Approval

Repros Blasts Off After FDA Study Clearance

Ambit Biosciences Files for IPO

Wall Street Is Betting P&G’s Dividend Growth Ends. The Cash Flow Suggests That’s Not Happening

Strategy (MSTR) vs BlackRock’s IBIT: Which Bitcoin Bet Has Held Up Better in 2026?

Social Security’s 2027 Raise Looks Like 3.8%. Here’s How Income Investors Give Themselves a Bigger One

Featured Reads

Her Physical Therapist Said Medicare’s $2,480 Limit Had Been Reached. That Number Is Not a Coverage Cap.

He "Retired" From Farming and Leased Out the Acres. Telling the Tenant What to Plant Kept Him Self-Employed.